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Abstract 
Background 
Several lines of evidence suggests that transcription factors are involved in the 
pathogenesis of Multiple Sclerosis (MS) but a complete mapping the whole network has 
been elusive. One of the reasons is that there are several clinical subtypes of MS and 
transcription factors which may be involved in one subtype may not be in others.  We 
investigated the possibility that this network could be mapped using microarray 
technologies and modern bioinformatics methods on a dataset from whole blood in 99 
untreated MS patients (36 Relapse Remitting MS, 43 Primary Progressive MS, and 20 
Secondary Progressive MS) and 45 age-matched healthy controls, 
Methodology/Principal Findings 
We have used two different analytical methodologies: a differential expression analysis 
and a differential co-expression analysis, which have converged on a significant number 
of regulatory motifs that seem to be statistically overrepresented in genes which are 
either differentially expressed (or differentially co-expressed) in cases and controls (e.g. 
V$KROX_Q6, p-value < 3.31E-6; V$CREBP1_Q2, p-value < 9.93E-6, V$YY1_02, p-value < 
1.65E-5).  
Conclusions/significance: Our analysis uncovered a network of transcription factors that 
potentially dysregulate several genes in MS or one or more of its disease subtypes. 
Analysing the published literature we have found that these transcription factors are 
involved in the early T-lymphocyte specification and commitment as well as in 
oligodendrocytes dedifferentiation and development. The most significant transcription 
factors motifs were for the Early Growth response EGR/KROX family, ATF2, YY1 (Yin and 
Yang 1), E2F-1/DP-1 and E2F-4/DP-2 heterodimers, SOX5, and CREB and ATF families.   
Introduction 
The impact of Multiple Sclerosis (MS) [1], an autoimmune disease characterised by 
chronic inflammatory demyelination of the central nervous system, is not widely 
appreciated by the general public, but the disorder affects millions of people worldwide 
and is the most common chronic disease of the central nervous system that begins in 
early to middle adult life [2] (its prevalence in the USA is 0.9 per 1,000 [3]). MS is a 
multifactorial and heterogeneous disease, and although its causes are currently 
unknown it is increasingly clear that both genetic and environmental factors contribute 
to susceptibility [2,4,5,6]. Evidence for genetic risk includes familial aggregation [5,7] 
and differences in prevalence between ethnic groups [8,9,10] (caucasians of Northern 
European ancestries appear to be particularly susceptible. Furthermore, it is now well 
established that certain genes influence susceptibility to MS – predominantly human 
leukocyte antigen (HLA) factors in the major histocompatibility complex (MHC) [11] and 
to a lesser extent IL2RA, IL7R, and CLEC16A [12,13,14,15,16], and others 
[17,18,19,20,21,22,23]. 
There are several clinical subtypes of MS, the most prevalent being: relapsing remitting 
(RRMS), where unpredictable relapsing episodes alternate with lengthier periods of 
remission (during remission there are no new signs of disease activity); primary 
progressive (PPMS), where there is steady progression of the illness from onset; and 
secondary progressive (SPMS), where after an initial relapsing remitting pattern, 
relapsing episodes are interspersed over progressive decline. A fourth subtype, 
progressive relapsing, is less common. The question of whether some MS subtypes are 
associated with particular susceptibility genes is open and merits further examination. 
Currently there are only a modest number of findings for such associations, including 
those of Refs. [24,25], and some of these have been challenged [26].  
Previous research has demonstrated the potential of differential gene expression 
profiling for elucidating complex traits, including disease susceptibility, when expression 
is measured in tissue related to the trait under study [27]. A companion study [28] to the 
work presented here applied a genome-wide association study of gene expression to 
MS. The expression of 48,000 probe sequences was measured in the mRNA 
transcriptome of whole blood in 99 untreated MS patients (36 RRMS, 43 PPMS, and 20 
SPMS) and 45 age-matched healthy controls, identifying over 19,000 genes expressed in 
the blood cells with a large number that were differentially expressed between the 
controls and MS sample groups. Functional profiling of the differentially expressed 
genes revealed that the cells in whole blood are more active in MS, being engaged in 
translation and energy production through oxidative phosphorylation to a greater 
extent. Additionally, T cells accounted for the greatest percentage of differentially 
expressed (in controls versus MS collectively) immune cell “tagging” genes. Together, 
these results are consistent with the prevailing view that autoreactive T cells play a key 
role in the pathogenesis of MS. 
Evidence suggests that transcription factors are involved in the pathogenesis of MS and 
other autoimmune diseases [29,30]. For example, it has previously been observed that 
members of the NF-kappaB, STAT, AP-1 and E2F families 
[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56], 
IRF-1 [36,46,47,57], IRF-2 [58], IRF-5 [59], IRF-8 [20],  CREB [36,46], PPARgamma and 
PPARalpha [60,61,62,63,64,65,66,67,68], SP1 [59], SP3 [69,70,71], RORC [72], NR4A2, 
TCF2 [73], ETS-1 [74] and FOXP3 [75,76,77,78,79,80,81,82,83,84,85] may be implicated 
in MS, its disease subtypes, and experimental autoimmune encephalomyelitis and other 
animal models of MS. This paper aims to complement a companion study by uncovering, 
thanks to combinatorial optimization methods and a more detailed analysis, 
transcription factors that potentially dysregulate many genes in MS. Ultimately, our goal 
is to piece together relationships and infer a network of transcription factors that are 
implicated in MS and its subtypes as inferred from the differential expression and co-
expression of several hundreds of genes. 
 
Results 
Two different analyses were used to uncover the transcription factors. The first 
identified genes differentially expressed between the four different groups in the 
study’s sample set; the second, groups of genes pair-wise differentially co-expressed 
between control and MS samples. The first analysis is better at revealing differences in 
gene expression between the sample groups, while the second aims to find specific 
groups of genes which have lost their normal pattern of co-expression and are affected 
by MS irrespective of disease subtype. Overrepresented binding motifs, and their 
corresponding transcription factors, were obtained for the groups of genes identified 
under both approaches. 
Analysis of Differential Gene Expression reveals that Binding Motifs for KROX/EGR 
Family, ATF2, and YY1 are Significantly Overrepresented in MS Subtypes  
This study employed two separate methodologies for analysing differentially expressed 
genes to identify sets of transcription factors as dysregulating candidates in MS.   
Seven molecular genetic signatures were derived from the whole blood mRNA 
expression data collected in [28] (our companion study) and then profiled for 
overrepresented TRANSFAC motifs. Each signature contains a set of probe sequences that 
are differentially expressed between a pair of sample groups specified by the signature’s 
denotation (C/MS, C/PP, C/RR, C/SP, PP/RR, RR/SP, or PP/SP); for example, C/PP 
contains genes differentially expressed between control and PPMS samples. The 
signatures were obtained using a three-step filtering process that discards the probes 
that are least relevant for distinguishing between the pair of sample groups according to 
formal criteria. First, a significance analysis of microarray (SAM) [86] was applied, then 
an entropy-based selection procedure [87], and finally, an ( ,β)-k-feature set selection 
method [88,89], which removes probes based on statistical significance, information 
content, and predictive ability respectively. This methodology has been used to identify 
robust biomarkers for a variety of diseases, including Alzheimer’s [88,90], Parkinson’s 
[91], and prostate cancer [92].  
Figures 1–7 depict the signatures and their corresponding clustered heatmaps. We note 
that the heatmap for C/MS (Figure 1) exhibits a lack of coherence in the MS samples, 
indicating that gene expression is heterogeneous over the MS group as a whole. 
Coherence increases when the MS subtypes are considered separately (Figures 2–7), 
suggesting a correlation between disease subtype and gene expression. The heatmaps 
containing SPMS samples (Figures 4, 5, and 7) are less coherent overall than those for 
PPMS (Figures 2, 5, and 6) and RRMS (Figures 3, 6, and 7), suggesting that SPMS is the 
most heterogeneous MS subtype with respect to gene expression in our study. A 
noticeable pattern of “bars” does appear in the PPMS samples in C/PP (Figure 2), 
though, which could be evidence of distinct PPMS subtypes with contrasting gene 
expression for the genes in the bars. 
A profile of overrepresented regulatory sequences was obtained for each of the seven 
signatures using the profiling tool GATHER [93]. The profiles contain TRANSFAC binding 
motifs occurring in the regulatory regions of a significantly greater proportion of the 
corresponding signature’s genes than expected (p-value < 0.05). The complete profiles 
for all signatures are given in Figure 9. Inspection of the profiles reveals that, with the 
exception of C/RR and C/SP, there is only a modest intersection between any pair of 
profiles. In contrast, half of the motifs in each of the C/RR and C/SP TRANSFAC profiles (six 
motifs) occur in the intersection of the pair. The C/RR and C/SP signatures share only 12 
gene probes (the signatures contain 267 and 113 probes respectively), which is not 
enough to account for the amount of agreement between their TRANSFAC profiles. In 
fact, the composition of the TRANSFAC profiles was unchanged when the 12 probes were 
removed from C/RR and C/SP and the profiles recomputed. These observations suggest 
that any pathways of transcriptional dysregulation occurring in MS are likely to be 
largely distinct in the PPMS subtype, while overlapping considerably in RRMS and SPMS. 
(We note a similar finding by Gandhi et al. [28]; they report that RRMS and SPMS share 
more dysregulated gene ontology pathways (principally immune regulation pathways) 
with each other than with PPMS.) 
Additionally, we profiled the above TRANSFAC profiles themselves to reveal higher-level 
overrepresented regulatory sequences. These higher-level regulatory sequences – which 
effectively identify ‘regulators of regulators’ – were obtained by TRANSFAC profiling the 
coding genes of transcription factors corresponding to key sequences in the above 
TRANSFAC profiles. We considered the identification of the key sequences to be a 
problem of combinatorial optimization (specifically, a generalization of the Hitting Set 
problem) as described under Materials and Methods. The resulting higher-level 
sequences are given in Figure 9 (HS column). We highlight the appearance of one of 
these sequences, a KROX/EGR motif (V$KROX_Q6), which is also very strongly indicated 
in the results below. 
Finally, we profiled up-/down regulated subsets of the signatures to reveal any 
regulatory sequences associated with increased/decreased expression only. Figure 10 
shows the complete profiles for each signature subset. We note a motif for the 
KROX/EGR family (V$KROX_Q6), which, along with two other motifs discussed later, is 
the most significantly overrepresented sequence identified by this study overall. Other 
very significant motifs were for ATF2 (V$CREBP1_Q2) and YY1 (V$YY1_02). We return to 
KROX/EGR, ATF2, and YY1 in the Discussion, where we examine their links to MS. 
Remarks on the presence of some probes in the genetic signature that discriminates 
Controls from MS patients  
The heterogeneity of the C/MS signature makes is relatively difficult to talk about 
individual probes, as it is unlikely that they will have the same pattern of expression 
across all subtypes of MS. Nevertheless, we highlight the following for future discussion. 
First, a probe for LOC649143 (similar to HLA class II histocompatibility antigen, DRB1-9 
beta chain precursor (MHC class I antigen DRB1*9) (DR-9) (DR9)) has a tendency to be 
consistently upregulated in controls but not in MS samples. Second, a probe for 
LOC650557 (similar to HLA class II histocompatibility antigen, DQ(W1.1) beta chain 
precursor (DQB1*0501)) has the opposite behaviour, a tendency to be downregulated in 
controls but upregulated in MS.  The complexities of the MHC locus in MS are possibly 
surfacing here [94]. Finally, several MS samples have higher expression for a probe of 
KIR2DS5 (Homo sapiens killer cell immunoglobulin-like receptor) [95,96] than in controls 
(KIR2DS5 was also part of a study of KIRs in [97]).  
Remarks on the presence of some probes in the genetic signature that discriminates 
Controls from PPMS patients  
FOXO3 [98,99,100,101] is downregulated in many of the PPMS samples.  Deficiency in 
FOXO3 leads to “spontaneous lymphoproliferation, associated with inflammation of 
several organs, in the absence of overt apoptotic defects. These findings correlated with 
the presence of hyperactivated helper T cells, which proliferated more vigorously and 
produced more Th1 and Th2 cytokines than their wild-type counterparts” [102]. FOXO3 
regulates, by inhibiting NF-kappaB activity [103], the tolerance and activation of T cells 
and is proposed as an inhibitor of inflammatory transcriptional activity [102].  
An interesting finding in this signature is the presence of a probe for HAR1A (highly 
accelerated region 1A (non-protein coding)). HAR1A was first identified in 2006 by 
Katherine Pollard et al. as part of a novel “RNA gene” expressed specifically in Cajal-
Retzius neurons in the developing human neocortex from 7 to 19 weeks of gestation 
[104] and co-expressed with reelin (which is an extracelluar matrix protein that is 
considered essential in the laminar organization of structures in the brain during 
development). Panteri et al. have reported that reelin is secreted by Schwann cells in 
the developing peripheral nerve, is dowregulated in adult stages, and induced following 
sciatic never injury. They have proposed reelin as a factor on the final calibre of 
myelinated axons and the absolute number of fibers per unit area in the peripheral 
nervous system [105]. What makes HAR1A somewhat unique is that it is one of the 
“highly accelerated regions” [106], where evolutionary mechanisms have created 
pressure for the emergence of “human-specific” brain features. HAR1A has been found 
by whole genome bioinformatics comparisons and is at centre stage of research on the 
functional genomic implications of these new non-coding RNA structures [104,107]. In 
the present study, HAR1A is one of two highly accelerated regions that we point to as 
interesting putative biomarkers; the other is in a protein-coding region and is discussed 
later. We highlight, however, the presence of SNHG5 (small nucleolar RNA host gene 5 
(non-protein coding)), located on chromosome 6q15 [108,109], in this signature. Both 
non-protein-coding probes warrant further investigation into the role that they may 
have in neurological diseases, especially MS.  
Other notable biomarkers include CD52, RNASE2, and EGR3 (upregulated in PPMS in 
comparison to Controls). The CD52 molecule (Cambridge pathology 1 antigen, 
CAMPATH-1 antigen) [110,111,112,113,114,115,116,117,118] is targeted by 
Alemtuzumab and there are recent reports that indicate that it may be an effective 
treatment for early MS [119]. RNASE2 (ribonuclease, RNase A family, 2 (liver, eosinophil-
derived neurotoxin))[120,121] is linked to the “Gordon phenomenon”, which is “the 
selective neuronal and axonal damage to white matter of cerebellum and spinal cord of 
experimental animals when injected intrathecally” [122].  The upregulation of EGR3 has 
apparently never been previously reported – neither in PPMS nor in other clinically 
defined subtypes of MS – and thus could be an important finding. EGR3 is a member of 
the KROX/EGR family of genes that code for immediate-early transcription factors 
[123,124], which regulate thymocyte proliferation during the transition from CD4-CD8- 
to CD4+CD8+ [125], and with EGR2 is a negative regulator of T-cell activation [126] and 
development (see [127,128,129]).  Experiments in mice show that together with 
EGR1/KROX-24 and SOX10, it cooperates to activate the Myelin Protein Zero (Mpz) 
intron element by EGR2 [130]. Jones et al. [130] report that “a conserved composite 
structure of Egr2/Sox10-binding sites in the genes encoding Mpz, myelin-associated 
glycoprotein and myelin basic protein genes was used to screen for similar modules in 
other myelin genes, revealing a potential regulatory element in the periaxin gene. 
Overall, these results elucidate a working model for developmental regulation of Mpz 
expression, several facets of which extend to regulation of other peripheral myelin 
genes.”  They also link EGR3 to myelination in Schwann cells, hence dysregulation of 
these concerted pathways may have consequences for neuropathies [131]. Later, we 
will return to the discussion of the KROX/EGR family of proteins, which are also linked to 
adaptation to stress and novelty [132], attention [133], and memory 
[134,135,136,137,138,139].   
Remarks on the presence of some probes in the genetic signature that discriminates 
Controls from RRMS patients  
We again note the presence of a probe for LOC649143 (similar to HLA class II 
histocompatibility antigen, DRB1-9 beta chain precursor (MHC class I antigen DRB1*9) 
(DR-9) (DR9)). Another probe that seems to be consistently upregulated in controls but 
not in MS samples is for HLA-DQB1 (major histocompatibility complex, class II, DQ beta 
1). This could be of interest because a sequence analysis conducted by Ramagopalan et 
al. have found strong evidence that the expression of the MHC class II Allele HLA-
DRB1*1501 is regulated by vitamin D [140]. The analysis involved sequencing the 
vitamin D response element (VDRE) in more than 1,000 chromosomes from HLA-DRB1 
homozygotes; they localised a single MHC (VDRE) to the promoter region of HLA-DRB1, 
while there was an important variation in non-MS-associated haplotypes [140]. We also 
observe a number of upregulated ribosomal protein genes (including RPS10, RPS14, 
RPL12, RPL24, etc) in this signature. 
With a different behaviour, we should cite a probe for VDR (Vitamin D (1,25- 
dihydroxyvitamin D3) receptor), and as in the C/MS signature, we have a probe for 
LOC650557 (HLA class II histocompatibility antigen, DQ(W1.1) beta chain precursor 
(DQB1*0501)) with a different trend (upregulation in MS).  
Other interesting biomarkers include CA2 (Carbonic anhydrase II) (downregulated in 
RRMS), IRF5 (Interferon Regulatory Factor 5) and CD3D (CD3d molecule, delta (CD3-T-
cell receptor complex)). CA2 is localized to oligodendrocytes, myelin, and choroid plexus 
epithelium in the human brain [141]. Using immunohistochemistry methods, Kida et al. 
report that: “CA II was found to be present not only in oligodendrocytes and choroid 
plexus epithelium (declining with aging in both these locations), but also in a subset of 
neurons mostly with GABAergic phenotype, in a few astrocytes, and transiently during 
brain development in the endothelial cells of microvessels. The enzyme also occurred in 
oligodendrocyte processes in contact with myelinating axons, myelin sheaths, and 
axolemma, but was either absent or appeared in minute amounts in compact myelin.” 
[141]. In 1996, Cammer reported delays on oligodendorcyte maturation in mutant mice 
deficient in CA2 [142,143].  
IRF5, SOD1, NF1 (neurofibromin 1), CD3D and ILF2/NF45 (interleukin enhancer binding 
factor 2, 45kDa), on the contrary, have a tendency to be upregulated in RRMS samples. 
An allele in IRF5 has been reported as conferring an increased risk for inflammatory 
bowel diseases, systemic lupus erythematosus and MS, suggesting that there is a link 
between IRF5 and several autoimmune diseases [59,144]. SOD1 and NF1 and their 
homologues have appeared in our gene ontology search as linked with several types of 
myelopathies and familial amyotrophic lateral sclerosis 
[145,146,147,148,149,150,151,152,153,154]. NF1 is expressed in cortical neurons and 
oligodendrocytes and sensory neurons and Schwann cells in the peripheral nervous 
system [155,156,157]. OMgp, the oligodendrocyte-Myelin glycoprotein gene, is within 
an intron of NF1 [158]. CD3D has a tendency to be upregulated in RRMS samples and is 
involved in TCR activation [159] and T-cell development [160,161,162]. 
 
Viral Pathways are Significantly Overrepresented in the genetic signature that 
discriminates between Controls and PPMS patients  
Each signature was functionally profiled using g:PROFILER [163], which integrates several 
profiling resources, including Gene Ontology, KEGG and Reactome pathways, and 
TRANSFAC sequence motifs. Only three of the signatures, C/MS, C/RR, and C/PP, had 
profiles containing significant terms, and are given in Supplementary Table S5. However, 
g:PROFILER’s significance test is considered to be very conservative, so profiles derived 
under a less stringent significance criterion, p-value < 0.005, are provided (Table S5). 
There is a group of nine ribosomal genes (RPL27, RPL35, RPL35A, RPL39, RPS5, RPS14, 
RPS15A, RPS27A, and RPLP0P2) in the C/PP signature that are responsible for almost all 
the terms in its profile (see Table S5). Most of these terms relate to influenza or 
translation pathways – principally translation initiation, translation elongation and 
influenza viral RNA transcription and replication. Although influenza itself is considered 
unlikely to be involved in MS, other viruses have been linked to autoimmune diseases. 
One viral theory of MS relates genetic sequences for viruses to similar sequences that 
code for the myelin sheath [164]. T cells adapted for the protein products of the virus 
sequence could mistakenly recognize myelin proteins as antigens and, were they to 
penetrate the blood-brain barrier, attack them in the brain [165,166]. Some viruses, 
including influenza, do contain genetic sequences that mimic human myelin protein 
coding sequences [164]. Furthermore, several studies have linked exacerbation of MS 
lesions to viral infection [167,168,169,170,171]; however, the studies usually target the 
relapsing forms of the disease rather than the primary progressive form, which is where 
we find the connection to these ribosomal proteins linked to a viral pathway. 
Binding Motifs for KROX/EGR Family, ATF2, and YY1 are Significantly 
Overrepresented  
We now consider regulatory sequences that are overrepresented in the signatures. A 
profile of regulatory sequences was obtained for each of the seven signatures using the 
profiling tool GATHER [93]. The profiles contain TRANSFAC binding motifs occurring in the 
regulatory regions of a significantly greater proportion of the corresponding signature’s 
genes than expected (p-value < 0.05). The complete profiles for all signatures and the 
ten most significant motifs found are given in Figure 9 and Table 1 respectively. 
Inspection of the profiles reveals that, with the exception of C/RR and C/SP, there is only 
a modest intersection between any pair of profiles (see Figure 9). In contrast, 
approximately half of the motifs in each of the C/RR and C/SP TRANSFAC profiles occur in 
the intersection of the pair. The C/RR and C/SP signatures share only 12 genes, which is 
not enough to account for the amount of agreement between their TRANSFAC profiles. In 
fact, the agreement between the profiles was completely unchanged when the 12 genes 
were removed from the two signatures and the TRANSFAC profiles recomputed. These 
observations suggest that, first, PPMS has a pattern of transcriptional dysregulation 
distinct from RRMS and SPMS, and second, RRMS and SPMS share pathways of 
transcriptional dysregulation.1 
In addition, we also profiled the above TRANSFAC profiles themselves to reveal higher-
level overrepresented regulatory sequences. These higher-level regulatory sequences – 
or “regulators of regulators” – were obtained by TRANSFAC profiling the transcription 
factor coding genes corresponding to key sequences in the above seven TRANSFAC 
profiles. We considered the identification of the key sequences to be a problem of 
combinatorial optimization (specifically, the hitting set problem) as described under 
Materials and Methods. The resulting higher-level sequences are given in Figure 9 (HS 
column). We highlight the appearance of one of these sequences, a KROX/EGR motif 
(V$KROX_Q6), which is very strongly indicated in the results below. 
Finally, we profiled up/down-regulated subsets of the signatures (defined in Figure 8) to 
reveal any regulatory sequences associated with increased/decreased expression only. 
Figure 10 shows the complete profiles for each signature subset. We note a motif for 
the KROX/EGR family (V$KROX_Q6), which along with two other motifs mentioned later 
is the most significantly overrepresented sequence identified by this study overall. Other 
very significant motifs were for ATF2 (V$CREBP1_Q2) and YY1 (V$YY1_02).  Table 1 lists 
the ten most significant motifs. We return to KROX/EGR, ATF2, and YY1 in the 
Discussion, where we examine their links to myelination and the immune response. 
Analysis of Differential Gene Co-Expression   
In this section, we report on the results of applying our second method of differential 
gene (co-)expression analysis. A kNN-MST clustering algorithm (described in [172,173]) 
was applied to the entire unfiltered whole genome mRNA expression data to produce a 
clustering of nodes.2 Each node corresponds to an mRNA probe sequence. Nodes are 
connected to its nearest neighbour according to a distance metric based on pair-wise 
differential co-expression (we refer to the Materials and Methods section for details). A 
pair of nodes whose expression is perfectly correlated in control samples and perfectly 
anti-correlated in MS samples (or vice versa) has a distance of zero; the distance 
increases as expression in controls and MS correlates better. In total, 448 clusters were 
found, 22 of which contain more than one hundred nodes. Figure 12 shows the 
seventeen largest clusters, one of which is depicted in greater detail in Figure 13. 
Of particular interest are nodes with many immediate neighbours – a configuration that 
we call a `star’. Each star contains a designated centre node and its immediate 
                                                 
1
 We note that Gandhi et al. (28. Gandhi KS, McKay FC, Cox M, Riveros C, Heard RN, et al. (2009) The 
multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of 
specific T cell pathways in pathogenesis.) have reported RRMS and SPMS share more dysregulated gene 
ontology pathways (principally immune regulation pathways) with each other than with PPMS. 
2
 More formally, the output is a forest, a collection of disjoint graphs such that each component is a tree 
(that is, a connected graph with no cycles). Each cluster corresponds to a particular tree in the forest. 
neighbours; a high cardinality star has a centre with at least twenty neighbours. A star 
indicates that a group of genes exhibit differential co-expression between control and 
MS samples (unlike the previous method, MS subtypes were not considered separately); 
more precisely, the co-expression of the centre with each neighbour (anti-)correlates 
over one sample group but not the other. To illustrate, a plot of the correlation 
behaviour of one star centre (a probe for INSR, Insulin Receptor) with its neighbours is 
shown in Figure 15. In total, there were 39 high cardinality stars; the members of these 
stars and their correlation plots are given in the supplementary material.  
Profiles containing overrepresented regulatory sequences were obtained for the 39 high 
cardinality stars. The members of the stars were assigned to one of 15 groups according 
to the cluster containing the star, which were profiled for overrepresented TRANSFAC 
binding motifs using GATHER [93]. Figure 11 shows the complete profiles for the 15 
groups. The three most significant motifs are for SOX5 (V$SOX5_01), the CREB family 
(V$CREB_Q4_01), and the CREB and ATF families (V$CREBATF_Q6). Again, we also 
obtained higher-level regulatory sequences (Figure 11, HS column); the two most 
significant were for the E2F-1:DP-1 heterodimer (V$E2F1DP1_0) and the E2F-4:DP-2 
heterodimer (V$E2F4DP2_01).  
A significantly large proportion of these motifs intersect with those in the TRANSFAC 
profiles of the signatures (see Figure 16). In particular, 80 motifs – or 78.4% of the 
signature motifs and 41.5% of the star motifs – occur in at least one star profile and one 
signature profile (the expected likelihood of this event under uniform random selection 
of motifs is less than one in 109, i.e. p-value < 10-9). A similar proportion occurs in the 
intersection between the star and up/down regulated signature subset profiles: 75 
motifs, or 77.3% of the up/down signature subset motifs and 38.9% of the star motifs 
(again: p-value < 10-9).  
The significant agreement between the two approaches is notable because patterns of 
differential expression and differential co-expression are unlikely to contain a large 
number of the same genes. This is indeed the case; there are 790 and 1,256 unique 
probes in the signatures and stars respectively, only 53 of these (6.7% and 4.2% 
respectively) occur in the intersection. The agreement in the regulatory motifs between 
both approaches could be explained by the occurrence of transcriptional dysregulation 
in MS, mediated by the transcription factors associated with these particular regulatory 
sequences. 
 
Remarks on the Composition of the set of “stars” 
We now highlight some of the probes that correspond to “stars”, seem to indicate genes 
that are differentially co-expressed in MS patients.  
ASPM (ASP (abnormal spindle) homolog, microcephaly associated (Drosophila)) is a 
centrosome protein [174] which initially was considered to be a major determinant of 
cortical size [175], but its function is now revisited [176,177,178,179], however its 
relatively recent positive selection status remain unquestioned.  Like HAR1, a highlight 
accelerated non-protein coding region we identified before when we reported the 
results of the gene expression signature, ASPM also holds key features that make us 
human [107], including perhaps language [180,181,182]. Deficits in ASPN’s functions has 
been consistently associated with neurodevelopmental disorders, primary in 
microencephaly [183,184,185,186,187,188].  
PTPRN (protein tyrosine phosphatase, receptor type, N), appears in the literature with 
different names (IA2, IA-2, IA-2/PTP, ICA3, ICA512, ICA 512, Islet cell antigen 512, Islet 
cell autoantigen 3). The literature reports associations with insulin dependent diabetes 
mellitus [189,190,191,192,193,194] and influences not only the secretion of hormones 
but also of neurotransmitters [195], brain development [196]. Disruption of PTPRN 
results in alterations in insulin secretion and glucose tolerance [197].   
 
A probe for INSR, the Insulin Receptor (probe ILMN_1670918), has lost its pattern of co-
expression with a group of 20 other probes. If the INSR has lost co-expression in MS with 
some other partner probes we should expect downstream effects on the insulin 
signaling pathway. Indeed, MAPK3 also belongs to the insulin signaling pathway and has 
also been identified centre of a star with 23 probes neighbours that have lost co-
expression with them. When we check for pathway information of all neighbours to the 
39 centres of stars, we observe using GATHER that the most statistically significant 
pathway is Insulin signaling (KEGG path:hsa04910, p-value < 0.0001, Bayes Factor 5), 
followed by Neuroactive ligand-receptor interaction (KEGG path:hsa04080, p-value < 
0.001, Bayes Factor 2) and Oxidative phosphorilation  (KEGG path:hsa00190, p-value < 
0.002, Bayes Factor 2). The 21 probes that appear in the Insulin signaling pathway are: 
EXOC7 (exocyst complex component 7), FASN (Fatty acid synthase), FLOT1 (Flotillin 1), 
FRAP1/MTOR (mechanistic target of rapamycin (serine/threonine kinase)), IKBKB 
(inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta),  INSR (Insulin 
receptor), MAPK3 (mitogen-activated protein kinase 3), MAPK6 (mitogen-activated 
protein kinase 6), PFKL (Phosphofructokinase, liver),  PFKP (phosphofructokinase, 
platelet),   PIK3CD (phosphoinositide-3-kinase, catalytic, delta polypeptide),  PIK3CG 
(phosphoinositide-3-kinase, catalytic, gamma polypeptide), PIK3R5 (phosphoinositide-3-
kinase, regulatory subunit 5), PPP1CB (protein phosphatase 1, catalytic subunit, beta 
isoform), PPP1CC (protein phosphatase 1, catalytic subunit, gamma isoform), PRKAA1 
(protein kinase, AMP-activated, alpha 1 catalytic subunit),  PRKAB2 (protein kinase, 
AMP-activated, beta 2 non-catalytic subunit), PRKAR2B (protein kinase, cAMP-
dependent, regulatory, type II, beta), PRKX (protein kinase, X-linked), RPS6KB1 
(ribosomal protein S6 kinase, 70kDa, polypeptide 1), SREBF1 (sterol regulatory element 
binding transcription factor 1). We also note that 17 out of these 21 (including INSR and 
MAPK3 themselves) have V$KROX_06 as a binding motif (TRANSFAC analysis) while all 
21 probes have a motif for V$E2F_Q6. These are the two motifs with the largest number 
of probes associated to them in this group of 21 gene, pointing again to the KROX family 
of proteins and E2F, now linked with insulin signaling regulation.  
The star corresponding to UniGene HS.495215 (T-cell antigen receptor alpha (TCRA), 
probe ILMN_1820392) has 56 neighbours. Of these 56, 15 have also appeared in one of 
our seven genetic signatures. With the exception of only one, they have appeared in 
either the signatures C/PP or C/RR. There is a relative big number of ribosomal proteins 
associated (RPL24, RPL27, RPL35, RPS10, RPS14, RPS17 (Ribosomal proteins L24, L27, 
L35, S10, S14, S25, S17), LOC441246 (ribosomal protein L35 pseudogene 5),  LOC285900 
(ribosomal protein L6 pseudogene 20), LOC646483 (ribosomal protein L6 pseudogene 
19). We have also found CD3D (CD3d molecule, delta (CD3-TCR complex)), GNL3/ 
Nucleostemin (guanine nucleotide binding protein-like 3 (nucleolar)) SNRPD2 (small 
nuclear ribonucleoprotein D2 polypeptide 16.5kDa), SEC11A/ Endopeptidase SP18  
(SEC11 homolog A (S. cerevisiae)),  TOMM7 (translocase of outer mitochondrial 
membrane 7 homolog (yeast)). The only downregulated gene (in a signature SP/PP) is 
MAD2L1BP (MAD2L1 binding protein).  From this group, it is perhaps CD3D and its the 
relationship with the TCRA locus that caught our immediate attention, since progress in 
the understanding of CD3D’s functions come from studies on its deficiency, defects 
and/or inactivation [161,198,199,200,201,202,203,204]. CD3D is a receptor involved in 
TCR activation [159] which has been recently found to be a biomarker for chronic graft-
versus-host disease in mononuclear cell samples from allogeneic hematopoietic stem 
cell transplantation recipients [205] and primary Sjögren's syndrome [206]. CD3D 
promotes the progression of early thymocytes towards the double positive-
stage[161,207,208]. GNL3/Nucleostemin, is a gene implicated in cell cycle/ growth/ 
progression[209,210], neural progenitor activity [211], which has also been linked to 
bipolar disorder [212]. However, upregulation of GNL3 may also lead to apoptosis [213]. 
Tsai et al. report in [214] that “overexpression of nucleostemin reduces cell proliferation 
in CNS stem cells and transformed cells. Mutation analysis indicates that excessive 
nucleostemin, particularly mutants that lack the GTP-regulatory domain, prevents cells 
from entering mitosis and causes apoptosis in a p53-dependent manner.”  
Interestingly, of the genes in the MS signature only three, two of which are ribosomal 
proteins, occur in any of the 39 highest cardinality stars (all three are neighbours rather 
than star centres). Of the 790 genes present in some signature, three are also star 
centres (PTPRN, underexpressed in C/RR; C20orf134, an uncharacterized protein 
overexpressed in C/PP, and Hs.443993, another uncharacterized transcribed locus 
overexpressed in PP/SP), while fifty appear as neighbours of star centres. Of these 53 
genes, sixteen (30%) appear in a single star, the star with centre Hs.495215 (T-cell 
antigen receptor alpha locus, TRAV38-1), most of which come from C/PP and C/RR. The 
TRAV38-1 star is strongly associated with ribosomal proteins. 
In the following section, we consider a plausible site of transcriptional dysregulation in 
MS – T cell specification – and identify a couple of transcription factors as particularly 
suspicious candidates. 
Discussion 
In this paper we have analysed gene expression data with a variety of computational 
methods with the aim of uncovering transcription factors that potentially dysregulate in 
MS or one or more of its disease subtypes. Tables 1–2 summarise the most significant 
transcription factors uncovered by our methods. Of these, the most significant are 
KROX/EGR family members, ATF2, YY1 (Yin and Yang 1), E2F-1/DP-1 and E2F-4/DP-2 
heterodimers, SOX5, and CREB and ATF families. Below we provide a brief review of 
some of these transcription factors, including information that potentially relates them 
to MS, such as any known regulatory roles in the expression of myelin proteins and 
association with other autoimmune diseases. 
The YY1 transcription factor (Yin and Yang 1) 
The zinc finger protein YY1 [217] can be a transcriptional activator or repressor of 
several genes (including those for ribosomal and nuclear –encoded mitochondrial 
proteins [218,219]) and has known roles in replication, cell proliferation, differentiation, 
and developmental processes [217,220,221,222,223]. It also regulates T-cell cytokine 
gene expression [224] and the immune response [225,226] and its relationships with 
viral replicating processes [227]. Experiments in mouse seem to indicate that the T-cell 
specific expression of CD3delta is regulated, in part, by YY1 which represses the 
promoter activity strongly in non-T cells [228]. The disruption of Epstein-Barr virus 
latency in B cells is induced by expression of BZLF1 inmediate-early protein, and this 
transcription is negatively regulated by YY1 [229]. A motif for inhibitory activity of YY1 
on the PrP gene has been observed. This is also interesting as the PrP knock-out mice 
exhibit resistance to transmissible spongiform encephalopathies [230]. The multiple 
functions of the YY1 transcription factor in the nervous system have been recently 
reviewed [231]. It has also been observed that YY1 enhances the transcription of the 
proteolipid protein (PLP) [232], one of the most abundantly expressed myelin proteins. 
In Ref. [233], Ai et al show that YY1 inhibits human papillomavirus (HPV) replication in 
vitro, and binds the human papillomavirus-6 E1 promoter. They suggest that both YY1 
appears negative regulators the differentiation-induced HPV-6 E1 promoter and the HPV 
life cycle (see also the link between YY1 and the long control region of HPV-16 as 
reported in [234]) Also Knutson, Oh and Broyles have recently reported that around 
“half of the intermediate and late gene transcriptional promoters of vaccinia virus have a 
binding site for the cellular transcription factor YY1 that overlaps the initiator elements”. 
Their conclusion is that YY1 functions by negatively regulating vaccinia virus promoters 
by binding to their initiator elements [235]. It also seems to be implied, together with 
SP1 and SP3 on the establishment or reactivation of varicella-zoster virus latency [236]. 
The non-structural protein NS of the Rift Valley fever virus interacts with the host 
protein SAP30 and with YY1, and as a consequence antagonize interferon-beta gene 
expression [237]. The Hepatitis C virus core interacts with the C-terminal end of the 
nucleolar phosphoprotein B23, and the recruitment of p300 together make a 
mechanism that reduces the repression effect of YY1 [238]. YY1 also regulates cis-acting 
negative elements in the Epstein-Barr virus BZLF1 promoter [239]. 
YY1 is considered a critical regulator of early B-cell development [240]. The perturbed 
expression of YY1 in the development of acute myeloid leukemia has been also 
highlighted by Erkeland et al. who observed that these gene tends to harbour viral 
integrations of the 1.4 strain of Graffi murine leukemia virus[241]. 
He, Sandoval and Casaccia-Bonnefil have studied the role of overexpression of YY1 in 
the differentiation of oligodendrocyte progenitors [242]. He et al., from the same group, 
have also shown that conditional ablation of YY1 in the oligodencrocyte linage gives 
phenotypes which have defective myelination, ataxia and tremor. YY1 is then seen as a 
transcriptional of the transcriptional inhibitors of myelin gene expression (Tcf4 and Id4), 
by a mechanism that includes the recruitment of HDAC1 to their promoters during 
oligodendrocyte differentiation [243] 
The EGR/KROX family 
As we said before, a motif for the Early Growth Response family (KROX/EGR family 
motif, V$KROX_Q6) was one of the three the most significantly overrepresented motifs 
identified by this study overall. A member of this family, EGR2/KROX-20 has been 
previously associated with the regulation of Schwann cells [244] (which in turn are 
known to be affected in some demyelinating disorders [245]) (see also [246,247]). Also 
in Schwann cells, progesterone has been shown to stimulate KROX-20 expression 
[248,249,250,251,252,253].  
 
Wakatsuki et al. recently reported that activation of KROX-20 is an “indispensable 
transcription factor for myelination”, concluding that “that meltrin-beta functions as a 
modulator of juxtacrine signaling from axons that activate the Akt pathway and the 
Krox-20 expression, which is the prerequisite for Schwann cell differentiation” [254].  
EGR1 and EGR3 (we have already observed the later as upregulated in PPMS in 
comparison to Controls) were reported by Jessen and Mirsky as providing a balance to 
EGR2/KROX-20 in Schwann cells. They hypothesise that this pair should be expressed 
previously to start myelination, be downregulated on myelination, but be back 
upregulated as Schwann cells dedifferentiate after injury [131] (see also [255,256,257]). 
Topiko et al. also point at an antagonist effect of EGR1 and EGR2 in Schwann cells [258].  
EGR1 has been previously pointed as disregulated in a genome-wide expression profiling 
analysis of synchronously differentiating olygodendrocytes generated from pure 
precursor cells in vitro, and comparing with the program of in vivo. In that study, Dugas 
et al. found a probe for EGR1 to be the most strongly expressed specifically in 
undifferentiated oligodendrocyte precursor cells [259]. A possible joint dysregulation of 
members of this family could be explored to see if they have a role in the differentiation 
of oligodendrocytes [260,261].  
 
As it was the case of the YY1 transcription factor, this family role in the immune 
response has to be monitored as there are reports as being negative regulators of T cell 
activation [126], having roles in T cell anergy [128,262,263,264,265], upregulation of Fas 
ligand [266] and TNF [267], CD154/CD40 ligand on CD4 T cells [268], autoreactive T cell 
activation [269], upregulation of cell cycle inhibitors p21(cip1) and p27(kip) (as studied 
in tolerant T cells following antigen challenge in vivo), interact with NF-kappaB p50 and 
p65 [270], regulate proinflammatory cytokines [271],  as well as thymocyte 
development [272,273].  
ATF2 and  SOX5  
Studying the homozygous shiverer mutant mice (shi/shi), Seiwa et al., have identified 
ATF2 as a regulator of the expression of MAG expression at a specific stage of shi/she 
oligodendrocyte differentiation [274].  Petro reported in 2005 that infection of 
macrophages by Theiler's murine encephalomyelitis virus induces a type of 
demyelination in mice that that that resembles human MS, and also observed induction 
of ATF2 30 minutes after the infection of macrophages [275].  Studying a mycobacterial 
antigen, Samten et al. report that ATF-2 might control expression of CREB and c-Jun 
during T cell activation and that of expression of IFN-gamma [276]. 
One of the other motifs for a transcription factor that was significantly overexpressed is 
SOX5 (p-value < 6.59E-6). Together with Sox6, Sox5 was identified by Stolt et al as cell-
autonomously regulating several stages of oligodendrocyte development in the mouse 
spinal cord (via repression of specification and terminal differentiation and influence 
migration patterns) [277].  
KROX/EGR Family and YY1 are Further Indicated by Involvement in T Cell 
Specification  
It is widely believed that T cells are central to the pathogenesis of MS; autoreactive T 
cells are hypothesised to coordinate an attack against central nervous system myelin, 
triggering an inflammatory response leading to neurological damage. However, the 
origin of the autoreactive lymphocytes is unknown. We looked for a correspondence 
between the regulators that we found above and those of T cell specification (the 
process by which haematopoietic stem cells progress through intermediate progenitor 
cell types to mature T cells), which may help to identify a defect in the T cell 
developmental program in MS. Such defects have been linked to many diseases, 
including a proposed contribution to diabetes susceptibility in non-obese diabetic mice, 
with CD4+CD8+ blasts that have abnormally high expression of IL-7Ralpha, and c-Kit 
[278]. 
Cell specification is well understood for T cells compared to most other cell types and 
many regulators of the process have been identified. In two recent comprehensive 
studies, a sizeable network of regulatory relationships involved in T cell specification was 
constructed [279] and the expression of more than 100 regulatory genes characterized 
in early T cell progenitors [280]. Table 7 lists the transcription factors that are known to 
participate in T cell specification [279,280] and which are indicated by our above 
analyses of differential expression as potentially playing a role in the pathogenesis of 
MS. The most significant are the KROX/EGR family and the Yin and Yang 1 transcription 
factor, which are both indicated in several different signatures and clusters.  
YY1, IKAROS  and other “legacy transcription factors” are relatively unchanged during early T-
lymphocyte specification and commitment 
T-cell lineage differentiation is an ongoing process in mammals with a clear transcription 
factor “armature” regulation [281] that is currently being thoroughly mapped by Ellen 
Rothenberg at Caltech and her group of collaborators [279,282,283]. Defects on the T-
cell developmental program have been linked to many diseases, including a proposed 
contribution to diabetes susceptibility in non-obese diabetic mice, with CD4+CD8+ blasts 
that have abnormally high expression of IL-7Ralpha, and c-Kit [278].  
To obtain a time-series of early T-cell development for gene expression analysis, David-
Fung et al. sorted subsets of immature mouse thymocytes from postnatal, weanling 
mice. Stages of development were based on the expression of CD44, CD25, and the 
growth factor receptor c-Kit and markers CD44, CD25 and the heat-stable antigen 
(CD24) and CD27. In the first stages of T-cell development the cells that enter the 
thymus are defined as “double negative” (DN), since they do not have the T-cell markers 
of maturity (CD4 and CD8). David-Fung et al, indexed these stages in terms of increasing 
maturity as DN1 (or early T-cell precursor, ETP), DN2, DN3a, DN3b, and DN4. Using four 
independent series of samples (from normal, young adult mice), DN1, DN2, total DN3, 
and DN4 cells were collected in each of the first two sets (“sets 1 and 2”, Series A). In the 
second two sets (“sets 4 and 5”, Series B) the DN3 cells were subdivided into DN3a (pre-
selection) and DN3b (the first stage past β-selection). 
YY1, together with Ikaros (Ikzf1), MYB and other transcription factors have been shown 
to have minimal changes from DN1 to DN3 stage. The list of other transcription factors 
that have critical roles in T-cell differentiation and development, and that have minimal 
changes of gene expression also includes MLL1, Gfi-1, GABPα, Stat5b, Oct1 (Pou2f1), 
and TOX. More recently, David-Fung et al have included YY1 together with FOG-1 
(Zfpm1), Gse1, and Zfp598 to this list of “legacy genes” [280]. This is in sharp contrast 
with other genes that have large changes in T-lineage gene expression. Examples include 
Aiolos (Ikzf3), Gata3 [284,285], and others that have clear patterns of upregulation 
during DN1 to DN3 progression (for the complete list see [280]). 
A Hypothetical Network of Transcription Factors that Dysregulate genes in MS  
If transcription factors do dysregulate genes in MS, it is reasonable to suspect that some 
are only associated with specific disease subtypes. Based on our data, we propose the 
following speculative, an informal initial model that links transcription factors to MS 
disease subtype. The model is limited to transcription factors currently known to be 
involved in T cell specification [279]. From these, it is informally constructed from those 
that match the transcription factors indicated by the TRANSFAC analysis of the signatures 
(see Figure 9), which distinguish between disease subgroups or between controls and 
disease subgroups.  
The model is illustrated in Figure 17. Each node in the model lists transcription factors 
that dysregulate in one of the node's outcomes (not identified). Under the model, 
dysregulation by RUNX1 characterises MS overall. Dysregulation by MYB divides MS 
individuals into two groups: one group develops PPMS or SPMS depending on LEF1 and 
Aiolos, while the other group develops either RRMS or SPMS depending on SCL, 
TCF1/LEF1, ETS1, RUNX2, and RUNX3. Note that under this model, SPMS is a 
heterogeneous group with two distinct pathways. 
The model is intended as a starting point to motivate further research for identifying 
transcription factors involved in the pathogenesis of MS, as it relies on simplifying and 
biologically naïve assumptions – for instance, T cell specification does not occur in 
peripheral blood, where the samples were collected, but in the thymus, but effects on 
peripheral blood are still measurable. Thus, there is room for refinement. Also, it could 
be extended by considering other transcription factors such as the key regulators 
identified by the hitting set analyses; the figure shows the key higher level regulators 
(regulators of regulators) as “others”. However, our hope is that this model can be used 
to corroborate other findings, single out transcription factors for more detailed 
research, and participate in unravelling some of the heterogeneity in MS.  
Conclusions 
Using state-of-the-art bioinformatics methods, our analysis uncovered a network of 
transcription factors that putatively contribute for the dysregulation of several genes in 
MS or one or more of its disease subtypes. Separate analytical methods were used on 
the same dataset, involving sophisticated mathematical algorithms to solve 
combinatorial optimization problems. We noted a convergence of findings, leading to a 
set of transcription factors which are involved in the early T-lymphocyte specification 
and commitment as well as in oligodendrocyte dedifferentiation and development. The 
most significant transcription factors motifs were for the Early Growth response 
EGR/KROX family, ATF2, YY1 (Yin and Yang 1), E2F-1/DP-1 and E2F-4/DP-2 heterodimers, 
SOX5, and CREB and ATF families.   
 
 
 
Materials and Methods 
Patients, Phenotyping, and Inclusion Criteria  
mRNA gene expression data for all known genes (48,000 probe sequences) was 
measured from peripheral blood samples of 144 individuals, 99 diagnosed with MS 
according to Poser and McDonald criteria [286,287] following the criteria in [288]. 
Patient demographics are given in Table 3. All patients had no immunomodulatory 
therapy for at least three months prior to sample collection and had written informed 
consent for participation.   
RNA Extraction, Microarray Protocols  
The peripheral blood samples were collected between 9AM and 1PM and total RNA was 
extracted from the whole blood in PAXgene tubes using PAXgeneTM Blood RNA kit 
(Qiagen, Germany) according to the manufacturer’s instruction unless otherwise stated. 
Total RNA quality was assessed and its concentration was measured using Agilent RNA 
6000 series II Nano kit (Agilent Technologies, CA). Minimum RNA Integrity Number (RIN) 
of 7 was employed for each sample to pass the quality assessment.  250 ng total RNA 
from each sample was biotinylated and amplified using Illumina® TotalPrep RNA 
Amplification Kit (Ambion, TX). Total RNA was reverse transcribed to synthesize first 
strand of cDNA followed by second strand synthesis. Double stranded cDNA was then 
transcribed and amplified in vitro to synthesize biotin labelled complementary mRNA 
(cRNA). The cRNA yield was measured at 260 nm using NanoDrop 1000A 
Spectrophotometer. 750 ng of cRNA sample was hybridized on a human HT-12 
expression beadchip (Illumina, Inc. CA) profiling 48,804 transcripts per sample. The chips 
were stained with streptavidin and scanned using an Illumina BeadArray Reader 
(Illumina, Inc. CA). 
Initial Filtering 
The average signal intensity for each gene was measured using Beadstudio v3. The 
sample signals were normalized with cubic spline in order to minimize variation due to 
non-biological factors. Approximately 19,000 genes were selected for differential 
expression analysis with detection p-value < 0.01 for at least one of all samples. The 
detection p-value measures the probability of observing signal without specific probe-
target hybridization. 
 
Analysis of Differential Expression 
A genetic ‘signature’ was obtained for each pair of sample groups using a three-step 
filtering process, which removed probes lacking sufficient discriminative power 
according to statistical significance, information content, and predictive ability 
respectively. 
1. First, a significance analysis of microarray (SAM) [86] was applied. 
2. Next, an entropy-based selection procedure employing Fayyad and Irani’s multi-
class, multi-interval discretisation algorithm [87] was applied. For each probe 
sequence, the algorithm finds the threshold that minimizes the class-information 
entropy of the samples, which discretises the dataset (greater than threshold – 
1; less – 0). It then discards the genes that do not sufficiently discriminate 
between the sample groups according to the minimum description length 
principle. 
3. Finally, an ( ,β) k-feature set selection method [88,89] was applied. The ( ,β) k-
feature set problem asks, in this context, for the smallest subset of probe 
sequences containing, first, at least  probes differentially expressed (after 
discretisation) between every pair of samples in the Cartesian product of the two 
sample groups (a probe is differentially expressed between a pair if their values 
are 0 and 1), and second, at least β probes with equal (discretised) value for all 
pairs over the Cartesian product of the sample groups. Intuitively,  and β 
specify the degree of inter-class differentiation and intra-class similarity 
respectively. In practise, we use  maximum and β maximal to facilitate 
computation of a solution; Table 4 gives the ( ,β) values (and various summary 
statistics) for each signature. We refer the reader to [88,90,91,92] for 
mathematical details and applications of the approach. 
Analysis of Differential Co-expression 
A cluster map was constructed for the approximately 19,000 probe sequences found to 
be expressed in whole blood, using a kNN-MST graph clustering analysis [172,173]. The 
map connects each probe to its nearest neighbour under the distance metric  
 (1) (2)2 ,ij ij ij ijd C C  
where dij is the distance between probes i and j, Cij
(k)  [-1,1] is the correlation between i 
and j in class k (class 1 is controls and class 2 is MS, all subtypes), and 
(1)2ij ijC . 
Correlation values are computed as a normalized sum of the Pearson and Spearman 
correlation coefficients, which is robust against outliers. The minimum distance between 
a pair of probe sequences is dij = 0, which occurs when the expression of i and j are 
perfectly correlated over controls and perfectly anti-correlated over disease (or vice 
versa). A distance of dij = 1, which is relatively short, occurs between a pair of probe 
sequences correlated (or anti-correlated) over controls and uncorrelated over disease.  
Hitting Set Filter 
Our hitting set filter is formally defined as follows. Consider a set S (of TRANSFAC motifs), 
a collection C of n subsets C1,…,Cn  S, and a positive integer m. The elements of S have 
positive weights ws (p-values), s  S. We seek a subset HS  S such that |HS  Ci|  m, 
i = 1,…,n, and s ws is minimal. Such a set HS, if it exists, is a weight-minimal hitting set 
because it ‘hits’ all subsets Ci at least m times.  
To illustrate, consider the hitting set instance given in the matrix below (left). Each 
subset Ci is defined by Ci = {sj | M(i, j) = ‘x’ }, where M(i,j) is the i,jth entry in the matrix 
below with the row for w removed; for example, C3 = {s1, s3, s5}. 
  S     
  s1 s2 s3 s6 s5  m HS  
 ws 5 6 6 7 8  1 s1  
C 
C1 x x x x x  2 s1, s5  
C2 x x  x x  3 s1, s2, s3, s5  
C3 x  x  x  4 No solution  
On the right, weight minimal solutions are shown for m = 1,…,4. Note that there is a 
two-fold effect as m grows: first, |HS| tends to increase with m; but second, beyond a 
certain point no satisfying HS exists. Throughout this paper, m = 1, 2, and 3. 
We employed CPLEX, an integer linear programming tool, to efficiently compute 
solutions to the hitting set instances. The hitting set problem can be formulated as an 
integer linear programming problem as follows 
 
minimise
such that 1, , ,
i
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s
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s C
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where xs = 1 if s  HS, xs = 0 otherwise.  
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Table S1. Excel file containing the TRANSFAC profiles for the 7 signatures, 14 up/down-
regulated signature subsets, and 15 star clusters. 
Tables S2-S4. The seven signatures and their expression heatmaps. For each signature, 
the probe Ids, expression values, hitting set annotation, and gene annotations are given. 
Table S5. Functional profiles for each signature. Profiling was performed with g:PROFILER 
[163], which integrates several profiling resources, including Gene Ontology, KEGG and 
Reactome pathways, and TRANSFAC sequence motifs. Note that a group of six ribosomal 
protein genes (RPL10A, RPL12, RPL39, RPS17, RPS21, and RPS25P8) are responsible for 
over half of the significant terms (17 of the 30) in the C/MS profile, and are linked to 
viral and translation pathways. Similarly, there is a group of nine ribosomal genes 
(RPL27, RPL35, RPL35A, RPL39, RPS5, RPS14, RPS15A, RPS27A, and RPLP0P2) that are 
responsible for almost all the significant terms in the profile for C/PP; most of these 
terms relate to influenza or translation pathways – principally translation initiation, 
translation elongation and influenza viral RNA transcription and replication.  
Table S6. Summary statistics of the ( ,β) k-feature set selection process for each of the 
signatures and combined listing of all signatures, showing over or under expression and 
signature overlap. 
Table S7. Complete member listing of all 39 high cardinality stars. 
Figure S8. Correlation plots for all high cardinality stars. 
Figure S9. The seventeen largest clusters found by analysis of genes differentially co-
expressed over controls and MS. 
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Figure Legends  
 
Figure 1. mRNA expression heatmap for the C/MS signature. Samples are placed along 
the horizontal axis and mRNA probe sequences along the vertical axis. Samples are 
colour-coded in the bottom horizontal bar (controls: blue; MS: green). Clustering with a 
high-performance memetic algorithm (described in [289]) has ordered the samples and 
probe sequences, revealing four quadrants that are primarily up- (red) or down- (green) 
regulated. Note that division into up/down regulated is more coherent in the control 
samples than the MS samples. 
 
Figure 2. mRNA expression heatmap for the C/PP signature. Control samples (blue), PPMS 
(grey). Note the pattern of ‘bars’ near the bottom right of the heatmap (circled) where expression broadly alternates 
between up- (red) and down- (green) regulated in disease. This regular pattern could indicate that PPMS contains 
distinct subgroups with respect to gene expression. 
 Figure 3. mRNA expression heatmap for the C/RR signature. Control samples (blue), 
RRMS (red). 
 
Figure 4. mRNA expression heatmap for the C/SP signature. Control samples (blue), 
SPMS (yellow). 
 
Figure 5. mRNA expression heatmap for the PP/SP signature. SPMS samples (yellow), 
PPMS (grey). 
 
Figure 6. mRNA expression heatmap for the PP/RR signature. RRMS samples (red), 
PPMS (grey). 
 
Figure 7. mRNA expression heatmap for the RR/SP signature. RRMS samples (red), 
SPMS (yellow). 
 
Figure 8. The A) up- and B) down-regulated signature subsets. (Note that when two 
groups were combined, the genes in the intersection are also included in the analysis).  
The most significant transcription factor motifs associated with a group are shown in 
square brackets. 
 Figure 9. TRANSFAC motif profiles for the seven signatures (blue bars). Only significant motifs (p-value  0.05) are shown. Bar size is proportional to the 
negative natural logarithm of p-value, which is also given as a number. Note that, in contrast to other pairs of profiles, there is a sizeable intersection 
between the C/RR and C/SP profiles (green ring). “Key” regulators of each profile, which are found by hitting set analysis, are indicated by dots underneath a 
bar (see figure legend). The TRANSFAC profile for the set containing all the key regulators’ coding genes is shown (orange bars); this profile in effect contains 
“higher level” regulators – i.e. a hierarchy with a next level of putative regulators of regulators. 
 Figure 10. TRANSFAC motif profiles for the up- (red bars) and down- (green bars) regulated signature subsets. Profiles for subset unions are also shown; for 
instance C/PP+C/RR contains the up (red) or down (green) regulated genes from the union of the C/PP and C/RR signatures (Figure 8 depicts all the signature 
subsets and subset unions.) The bottom row (blue bars) is the profile for all genes in the C/PP, C/RR and C/SP signatures. Size of bar is proportional to the 
negative natural logarithm of p-value, which is also given as a number. Only significant motifs (p-value  0.05) are shown. 
 
Figure 11. TRANSFAC motif profiles for the fifteen clusters found by correlation clustering (cyan bars). Only “key” regulators of each profile, which are found by hitting set 
analysis (see figure legend), are shown. The TRANSFAC profile for the set containing all the key regulators’ coding genes is shown (orange bars); this profile in effect 
contains “higher level” regulators – regulators of regulators. Size of bar is proportional to the negative natural logarithm of p-value, which is also given as a number. Only 
significant motifs (p-value  0.05) are shown.  
 Figure 12. The seventeen largest clusters resulting from using a distance measure based on changes in correlation 
of gene expression between classes.   
 
Figure 13. The largest cluster from Figure 12 with a different layout. Nodes represent probes, 
colour and size indicate its centrality in the graph (number of connected nodes).  Some of the 
prominent “stars” have been labelled. 
 
Figure 14. Correlation of scaled expression values of star centre HS.495215 (T-cell antigen receptor alpha) (purple line) with the average of negatively (left column) and positively (right 
column) correlated neighbour probes (coloured dots). The light blue vertical line separates control samples to the left and MS to the right.  The figures show three different orderings: by 
the harmonic mean of neighbours (top row), by the star centre expression value (middle row) and by the difference between star centre and neighbours average (bottom row).  The class 
correlation values of star centre with neighbours are shown in the top figure; for example, r(-,C) is correlation coefficient of negatively correlated probes with control samples and r(+,MS) is 
the correlation of positively correlated probes with MS samples.  Dot colours indicate sample class: green – control, blue – PPMS, red – RRMS, yellow – SPMS. These graphs illustrate 
patterns of differential expression in Control versus MS samples. In particular, on the left it can be observed that some neighbours are strongly anti-correlated with the star centre in 
controls (correlation coefficient -0.629) but weakly correlated in MS (0.184); on the right, the remaining neighbours are strongly correlated with the centre in controls (0.788) but weakly 
anti-correlated in MS (-0.145). 
 Figure 15. Correlation plot for the insulin receptor star centre (INSR).  Some neighbours are strongly anti-correlated with the centre in controls (correlation coefficient -0.744) but weakly 
correlated in MS (0.130); the remaining neighbours are strongly correlated with the centre in MS (0.739) but weakly anti-correlated in MS (-0.233). See Figure 14 for a detailed explanation of 
this figure. 
 
Figure 16. Number of motifs found in common between the different analytical 
approaches. Number of motifs occurring in the A. signature profiles, B. up/down 
regulated signature subset profiles, and C. cluster profiles. 
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Signature Transcription  
Factor  
Motif  
C/PP MYB V$VMYB_01 
C/SP RUNX1,  
 RUNX2, V$AML_Q6 
 RUNX3  
RR/SP SCL V$TAL1_Q6 
 TCF1/LEF1 V$LEF1TCF1_Q4 
 ETS1 V$CETS1P54_01 
PP/SP LEF1 V$LEF1_Q6 
 Aiolos V$IK3_01 
 
The transcription factors motifs below were 
indicated in the following signatures. 
Figure 17. Speculative initial sketch for a model of transcription factors currently known 
to be involved in T cell specification and which may also be involved in the pathogenesis 
of MS, showing links to disease subtype. Other transcription factors that also need to be 
added to this model are those which we have found very relevant in our analysis such as 
the Early Growth response EGR/KROX family, ATF2, YY1 (Yin and Yang 1), E2F-1/DP-1 and 
E2F-4/DP-2 heterodimers, SOX5, and CREB and ATF families.   
 Tables 
 
Table 1. The most significantly overrepresented TRANSFAC motifs found in this 
study. 
 Binding motif  Transcription Factor Profile p-value 
 Via profiling the signatures 
1. V$CREBP1CJUN_01 (M00041) ATF2/c-Jun heterodimer C/SP 1.38E-4 
2. V$ATF_B (M00338) ATF family C/SP 1.92E-4 
3. V$TEL2_Q6 (M00678) TEL2 C/PP 2.41E-4 
4. V$CREB_Q2 (M00177) CREB C/RR 6.49E-4 
5. V$VMYB_01 (M00003) V-MYB C/PP 8.01E-4 
6. V$ELK1_02 (M00025) ELK1 C/RR 8.67E-4 
7. V$CETS1P54_01 (M00032) ETS1 RR/SP 8.67E-4 
8. V$HNF3B_01 (M00131) HNF3β (FOXA2) C/MS 9.03E-4 
9. V$CREBP1_Q2 (M00179) ATF2 C/SP 1.14E-3 
10. V$ATF_B (M00338) ATF family C/RR 1.63E-3 
 Via profiling the up/down regulated signature subsets 
1. V$KROX_Q6 (M00982) KROX/EGR family C/PP+C/RR (-) 3.31E-6 
2. V$KROX_Q6 (M00982) KROX/EGR family C/PP+C/RR+C/SP (-) 6.59E-6 
3. V$CREBP1_Q2 (M00179) ATF2 C/PP+C/RR+C/SP (+) 9.93E-6 
4. V$CREBP1_Q2 (M00179) ATF2 C/RR+C/SP (+) 1.65E-5 
5. V$CREBP1_Q2 (M00179) ATF2 C/SP (+) 1.65E-5 
6. V$YY1_02 (M00069) YY1 C/PP+C/RR+C/SP (+) 1.65E-5 
7. V$CREBP1CJUN_01  (M00041) ATF2/c-Jun heterodimer C/SP (+) 3.30E-5 
8. V$YY1_02 (M00069) YY1 C/PP+C/RR (+) 4.28E-5 
9. V$CREBP1CJUN_01  (M00041) ATF2/c-Jun heterodimer C/RR+C/SP (+) 1.19E-4 
10. V$YY1_02 (M00069) YY1 C/PP+C/SP (+) 1.22E-4 
 Via profiling the star groups 
1. V$E2F1DP1_01 (M00736) E2F-1/DP-1 heterodimer HS 3.31E-6 
2. V$E2F4DP2_01 (M00739) E2F-4/DP-2 heterodimer HS 3.31E-6 
3. V$SOX5_01 (M00042) SOX5 final_1 6.59E-6 
4. V$CREB_Q4_01 (M00917) CREB family final_2 6.59E-6 
5. V$CREBATF_Q6 (M00981) CREB and ATF families final_1 9.93E-6 
6. V$HTF_01 (M00538)  final_12 1.65E-5 
7. V$E2F_Q4 (M00426) E2F/DP heterodimers final_2 2.65E-5 
8. V$E2F1_Q6_01 (M00940) E2F-1 final_2 2.65E-5 
9. V$NRF2_01 (M00108) NFE2L2 (NRF2) final_10 2.65E-5 
10. V$MINI20_B (M00324)  final_1 3.30E-5 
In the Profile column, (+) and (-) indicate up- and down-regulated subsets respectively. The '+' in names like C/PP+C/RR (-) 
indicates the union of the named signatures. 
 
Table 2. The 25 most significantly overrepresented binding motifs/transcription 
factors that have coding genes involved in T cell specification.  
 
Binding motif 
Transcription 
factor Profile Gene(s)  p-value 
1. V$KROX_Q6 (M00982) EGR family C/P+C/R(-) EGR1, EGR2, EGR3 3.31E-06 
2. V$YY1_02 (M00069) YY1 C/P+C/R(+) YY1 1.65E-05 
3. V$KROX_Q6 (M00982) EGR family C/R(-) EGR1, EGR2, EGR3 6.25E-05 
4. V$KROX_Q6  (M00982) EGR family HS EGR1, EGR2, EGR3 2.03E-04 
5. V$YY1_02 (M00069) YY1 C/P(+) YY1 2.41E-04 
6. V$KROX_Q6 (M00982) EGR family C/R+C/S(-) EGR1, EGR2, EGR3 4.62E-04 
7. V$ER_Q6 (M00191) ER All genes ESR1 4.62E-04 
8. V$CETS1P54_01 (M00032) C-ETS-1(P54) RR/SP ETS1 8.67E-04 
9. V$E2F_Q3_01 (M00918) E2F All genes TFDP1 1.84E-03 
10. V$CDP_01 (M00095) CUTL1 C/P+C/R(-) ETS1 2.09E-03 
11. V$YY1_02 (M00069) YY1 C/P+C/S(+) YY1 2.22E-03 
12. V$EBF_Q6  (M00977) EBF final_53 EBF 2.48E-03 
13. V$ER_Q6 (M00191) ER C/P+C/R(+) ESR1 2.63E-03 
14. V$KROX_Q6  (M00982) EGR family final_25 EGR1, EGR2, EGR3 2.74E-03 
15. V$ER_Q6 (M00191) ER C/MS ESR1 2.74E-03 
16. V$OCT1_Q6  (M00195) OCT1 final_25 POU2F1 3.06E-03 
17. V$EBF_Q6  (M00977) EBF final_25 EBF 3.21E-03 
18. V$KROX_Q6 (M00982) EGR family HS EGR1, EGR2, EGR3 3.21E-03 
19. V$CETS1P54_01  (M00032) C-ETS-1(P54) final_63 ETS1 3.38E-03 
20. V$TCF1P_Q6  (M00670) TCF1 final_63 YY1 3.38E-03 
21. V$KROX_Q6 (M00982) EGR family C/P(-) EGR1, EGR2, EGR3 3.38E-03 
22. V$IK3_01 (M00088) IK-3 PP/SP AIOLOS 4.99E-03 
23. V$KROX_Q6 (M00982) EGR family All genes EGR1, EGR2, EGR3 5.92E-03 
24. V$E2F_Q3_01 (M00918) E2F C/P+C/R(-) TFDP1 5.92E-03 
25. V$ER_Q6 (M00191) ER C/S(-) ESR1 6.22E-03 
Profile identifies the TRANSFAC profile (‘HS’ is the hitting set profile for the signatures, see Figure 9; ‘All genes’ is the 
profile for the union of all genes in the C/PP, C/RR, C/SP signatures. Gene(s) gives the corresponding T cell 
specification regulatory genes identified in [279,280]. 
 
 Table 3. Demographics of patient and control cohorts. 
Sample  N M:F Age Age at 
diagnosis 
Duration EDSS 
Controls  45 16:29 
48.5       
(23-77)    
MS  99 33:66 
54 35.5 16.5 4.5 
(29-87) (16-59) (1-54) (0-9) 
PPMS  43 21:22 
55.3 42 13 5.6 
(30-87) (21-58) (5-31) (2-8) 
RRMS  36 7:29 
48.5 33 15 2.7 
(29-65) (19-56) (1-36) (0-6.5) 
SPMS  20 5:15 
57.5 35.5 22 6.5 
(34-73) (16-59) (2-54) (4-9) 
M:F male:female; EDSS – expanded disability scale; mean and range are shown. 
 
 
Table 4. Summary of (α,β) k-feature set selection results for each signature. 
       0-Centered 1-Centered 
 #0 #1 # EntF Nalfa Amax #ABK Nbeta Bmax Bmxml Nbeta Bmax Bmxml 
C/MS 45 99 369 4455 40 145 990 232 79 4851 107 58 
C/PP 45 43 360 1935 66 221 990 209 113 903 170 113 
C/RR 45 36 366 1620 73 260 990 235 154 630 160 131 
C/SP 45 20 317 900 40 113 990 245 67 190 124 67 
PP/SP 43 20 133 860 23 77 903 90 48 190 83 53 
RR/PP 36 43 126 1548 25 86 630 82 55 903 75 49 
RR/SP 36 20 113 720 24 66 630 66 32 190 80 48 
#0, #1 are the number of samples in class 0 and class 1 (for example, in the C/MS signature, class 0, Controls, has 45 samples 
and class 1, MS, has 99 samples). #EntF is the number of features (probes) satisfying the entropy filtering criterion. Nalfa is the 
number of alpha pairs. A-max is the maximum number of features for all alpha-pairs. #ABK is the size of the optimum solution 
(signature size). Nbeta is the number of beta pairs, considering only one class. B-max is the maximum number of features for all 
beta-pairs. Bmxml is the maximum number of features per beta-pair before the solution increases in size. 0-Centered/1-
Centered refers to the search for in-class coherency for class 0 and class 1 respectively.   
 
 
 
 
